Increased efficacy of the immunoglobulin G2a subclass in antibody-mediated protection against lactate dehydrogenase-elevating virus-induced polioencephalomyelitis revealed with switch mutants.
Immunoglobulin G1 (IgG1), IgG2a, and IgG2b switch variants were derived from an IgG3 monoclonal antibody directed against the VP3 envelope glycoprotein of lactate dehydrogenase-elevating virus (LDV). Among the four antibodies, IgG2a delayed the onset and progression of LDV-induced polioencephalomyelitis more than did the other subclasses. This suggests that the IgG2a predominance observed in many IgG antibody responses elicited by live viruses could, at least under some circumstances, correspond to the selection of the best protection for the infected host.
Markine-Goriaynoff
Dominique
D
Unit of Experimental Medicine, Christian de Duve Institute of Cellular Pathology, Université Catholique de Louvain, 1200 Brussels, Belgium.
Coutelier
Jean-Paul
JP
D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000627:therapeutic use; D000914:Antibodies, Viral / Q000235:genetics / Q000627:therapeutic use*; D004679:Encephalomyelitis / Q000628:therapy* / Q000821:virology*; D005260:Female; D016867:Immunocompromised Host; D007074:Immunoglobulin G / Q000235:genetics / Q000627:therapeutic use*; D007772:Lactate dehydrogenase-elevating virus / Q000276:immunology; D051379:Mice; D027041:Somatic Hypermutation, Immunoglobulin
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D007074:Immunoglobulin G